Ferroptosis-centered Disease Response Information
General Information of the Disease (ID: DIS00016)
| Name |
T-cell lymphoma
|
||||
|---|---|---|---|---|---|
| ICD |
ICD-11: 2B01
|
||||
Full List of Target(s) of This Ferroptosis-centered Disease
Cystine/glutamate transporter (SLC7A11)
| In total 1 item(s) under this target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | |||
| Target for Ferroptosis | Suppressor | |||
| Responsed Disease | NK/T cell lymphoma [ICD-11: 2B01] | |||
| Responsed Drug | Kayadiol | Investigative | ||
| Responsed Regulator | Cellular tumor antigen p53 (TP53) | Driver | ||
| Pathway Response | Ferroptosis | hsa04216 | ||
| Cell Process | Cell ferroptosis | |||
| In Vitro Model | YT cells | Natural killer cell lymphoblastic leukemia | Homo sapiens | CVCL_1797 |
| hPBLs (Human peripheral blood lymphocytes) | ||||
| Response regulation | Kayadiol decreased the expression of SLC7A11 and GPX4, the negative regulatory proteins for ferroptosis. And p53 was the key mediator of kayadiol-induced ferroptosis by SLC7A11/GPX4 axis through p53 knockout experiments. Kayadiol can serve as an effective alternative in the treatment of NK/T cell lymphoma. | |||